表观遗传学标志物在肿瘤液体活检中的研究进展  

Research Progress of Epigenetic Markers in Tumor Liquid Biopsy

作　　者：刘浩[1] 周云 卢瑗瑗[1] LIU Hao;ZHOU Yun;LU Yuanyuan(State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases Xijing Hospital of Digestive Diseases,Fourth Military Medical University,Xi’an,710032,China;Department of Gastroenterology,Tangdu Hospital,Fourth Military Medical University,Xi’an 710038,China;College of Life Sciences,Northwest University,Xi’an 710069,China)

机构地区：[1]第四军医大学,西京消化病医院,国家消化系统疾病临床医学研究中心和消化系肿瘤整合防治全国重点实验室,西安710032 [2]空军军医大学唐都医院消化内科,西安710038 [3]西北大学,生命科学学院,西安710069

出　　处：《中国细胞生物学学报》2023年第12期1844-1854,共11页Chinese Journal of Cell Biology

基　　金：国家自然科学基金(批准号:82303489、82273142);国家重点研发计划(批准号:2022YFC2505104)资助的课题。

摘　　要：与传统组织活检相比,液体活检具有无创、实时动态监测、克服肿瘤异质性等诸多优势,是极具潜力的肿瘤早筛早诊工具。肿瘤的发生发展伴随着异常的表观遗传学的改变,如DNA甲基化、组蛋白修饰、非编码RNA调控等。通过液体活检检测这些表观遗传标志物的变化已被应用于肿瘤的早诊早筛、复发监测、肿瘤亚型鉴定以及对治疗反应和结果预测等方面,并展现出极大的应用前景。该文就目前表观遗传学标志物检测在肿瘤液体活检中的研究进展进行综述。Compared with traditional tissue biopsy,liquid biopsy has many advantages,such as non-invasive,real-time dynamic monitoring,overcoming tumor heterogeneity,and so on.It is regarded as a promising tool for early screening and diagnosis of cancer.Tumor development and progression are accompanied by abnormal epigenetic changes,such as DNA methylation,histone modification,and non-coding RNA regulation.The detection of these epigenetic markers by liquid biopsy has been applied in early diagnosis and screening of tumors,recurrence monitoring,identification of tumor subtypes,and prediction of treatment response and outcomes,And it has shown great application prospects.This review summarizes the progress of epigenetic marker detection in tumor liquid biopsy.

关 键 词：肿瘤 液体活检 表观遗传学 生物标志物 

分 类 号：R730.4[医药卫生—肿瘤]